Pacific Biosciences of California Inc. (NASDAQ: PACB) is -25.68% lower on its value in year-to-date trading and has touched a low of $2.20 and a high of $6.07 in the current 52-week trading range. The PACB stock was last observed hovering at around $3.82 in the recent trading session, with the current gains setting it 0.11%.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
At last check, trading at $3.93, the stock is 8.50% and 9.64% above its SMA20 and SMA50 respectively. However, with a current trading volume of 0.57 million and changing 2.88% at the moment leaves the stock -6.83% off its SMA200. PACB registered -36.33% loss for a year compared to 6-month loss of -22.36%. The firm has a 50-day simple moving average (SMA 50) of $3.6585 and a 200-day simple moving average (SMA200) of $3.8129.
The stock witnessed a -2.05% gain in the last 1 month and extending the period to 3 months gives it a 34.04%, and is 10.72% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.80% over the week and 6.61% over the month.
Pacific Biosciences of California Inc. (PACB) has around 404 employees, a market worth around $568.19M and $90.10M in sales. Profit margin for the company is -58.30%. Distance from 52-week low is 78.64% and -35.26% from its 52-week high. The company has generated returns on investments over the last 12 months (-116.60%).
Pacific Biosciences of California Inc. (PACB) Analyst Forecasts
Pacific Biosciences of California Inc. quarterly earnings per share for the current quarter are estimated at -$0.18 with sales reaching $13.72M over the same period.The EPS is expected to grow by 27.30% this year, but quarterly earnings will post -8.60% year-over-year.
Pacific Biosciences of California Inc. (PACB) Top Institutional Holders
205 institutions hold shares in Pacific Biosciences of California Inc. (PACB), with 6.68M shares held by insiders accounting for 4.33% while institutional investors hold 91.93% of the company’s shares. The shares outstanding are 153.45M, and float is at 148.77M with Short Float at 10.80%. Institutions hold 87.94% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 12.83 million shares valued at $39.27 million. The investor’s holdings represent 8.32% of the PACB Shares outstanding. As of Mar 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 7.47 million shares valued at $22.85 million to account for 4.84% of the shares outstanding. The other top investors are Bellevue Group AG which holds 7.38 million shares representing 4.78% and valued at over $22.58 million, while Capital International Investors holds 4.40% of the shares totaling 6.8 million with a market value of $20.8 million.
Pacific Biosciences of California Inc. (PACB) Insider Activity
A total of 8 insider transactions have happened at Pacific Biosciences of California Inc. (PACB) in the last six months, with sales accounting for 3 and purchases happening 5 times. The most recent transaction is an insider sale by Phillips James Michael, the company’s SVP, Research & Development. SEC filings show that Phillips James Michael sold 2,760 shares of the company’s common stock on Mar 24 at a price of $3.05 per share for a total of $8421.0. Following the sale, the insider now owns 0.25 million shares.
Pacific Biosciences of California Inc. disclosed in a document filed with the SEC on Feb 20 that Hunkapiller Michael (Chairman, CEO & President) sold a total of 166,575 shares of the company’s common stock. The trade occurred on Feb 20 and was made at $4.50 per share for $0.75 million. Following the transaction, the insider now directly holds 1.87 million shares of the PACB stock.
Still, SEC filings show that on Feb 20, Phillips James Michael (SVP, Research & Development) disposed off 5,050 shares at an average price of $4.48 for $22624.0. The insider now directly holds 251,980 shares of Pacific Biosciences of California Inc. (PACB).
Pacific Biosciences of California Inc. (PACB): Who are the competitors?
The company’s main competitors (and peers) include Thermo Fisher Scientific Inc. (TMO) that is trading 30.22% up over the past 12 months. Illumina Inc. (ILMN) is -1.95% down on the 1-year trading charts. Short interest in the company’s stock has fallen -2.92% from the last report on May 14, 2020 to stand at a total of 16.54 million short shares sold with a short interest ratio of 12.41.